CAS 1233948-35-0

ELR510444

Description:

ELR510444, identified by its CAS number 1233948-35-0, is a chemical compound that has garnered attention in pharmaceutical research, particularly for its potential therapeutic applications. While specific characteristics such as molecular structure, solubility, and reactivity may vary, compounds in this category are often evaluated for their biological activity, pharmacokinetics, and safety profiles. Typically, such substances undergo rigorous testing to determine their efficacy against targeted diseases, alongside assessments of their stability and compatibility with other compounds. The compound may exhibit specific functional groups that influence its interaction with biological systems, making it a candidate for drug development. Additionally, its synthesis and formulation are crucial for ensuring optimal delivery and bioavailability in therapeutic contexts. As research progresses, detailed studies will provide more comprehensive insights into its properties and potential applications in medicine.

ELR-510444

CAS: 1233948-35-0

Formula: C₁₉H₁₆N₂O₂S₂

Purity: 98%

Color and Shape: Solid

Molecular weight: 368.4725

Ref: IN-DA009CBB

N-(5-(5-Cyanothiophen-2-Yl)-2-Methylphenyl)-4-Methylbenzenesulfonamide

CAS: 1233948-35-0

N-(5-(5-Cyanothiophen-2-Yl)-2-Methylphenyl)-4-Methylbenzenesulfonamide

Purity: 98+%

Molecular weight: 368.47g/mol

Ref: 54-OR1024343

ELR510444

CAS: 1233948-35-0

ELR510444

Purity: ≥95%

Molecular weight: 368.47g/mol

Ref: 54-BUP10791

ELR510444

CAS: 1233948-35-0

ELR510444 (LR510444) is a novel microtubule disruptor; inhibits MDA-MB-231 cell proliferation with IC50 of 30.9 nM.

Formula: C₁₉H₁₆N₂O₂S₂

Purity: 97.67% - 98.69%

Color and Shape: Solid

Molecular weight: 368.47

Ref: TM-T2060

ELR510444

CAS: 1233948-35-0

ELR510444 is a small molecule that inhibits the expression of survivin, an apoptosis protein. ELR510444 has potent antitumor activity and is currently being evaluated in clinical trials for the treatment of cervical cancer and renal cell cancer. This drug is being developed by Eli Lilly and Company. ELR510444 also has antiangiogenic properties, which may be due to its ability to inhibit tumor growth by blocking the growth factor VEGF signaling pathway. The mechanism of action of ELR510444 is still under investigation, but it has been shown to bind to the drug transporter ABCG2 and inhibit cellular proliferation in vitro.
ELR510444 was docked against a number of proteins implicated in cancer progression including EGFR, HER2, MET, PIK3CA, and AKT1 using molecular docking analysis. It was found that ELR510444 binds to these proteins with high affinity (Kd = 0.6-0.7 nM) and

Formula: C₁₉H₁₆N₂O₂S₂

Purity: Min. 95%

Molecular weight: 368.47 g/mol

Ref: 3D-IZB94835